Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

3.560 +0.040 (+1.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 60,847
Open 3.580
Bid (Size) 3.430 (10)
Ask (Size) 3.640 (3)
Prev. Close 3.520
Today's Range 3.520 - 3.600
52wk Range 0.5100 - 15.06
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday?
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill

Performance

YTD
+196.7%
+196.7%
1 Month
+415.9%
+415.9%
3 Month
+249.0%
+249.0%
6 Month
+173.8%
+173.8%
1 Year
-42.6%
-42.6%

More News

Read More
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Friday?
Via Chartmill
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
Via Benzinga
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits
Via Benzinga
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels
Via Benzinga
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential
Via Benzinga
Alzamend Neuro to Present at the Sequire Investor Summit
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Via PressReach
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
Via Benzinga
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire

Frequently Asked Questions

Is Alzamend Neuro, Inc. - Common Stock publicly traded?
Yes, Alzamend Neuro, Inc. - Common Stock is publicly traded.
What exchange does Alzamend Neuro, Inc. - Common Stock trade on?
Alzamend Neuro, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alzamend Neuro, Inc. - Common Stock?
The ticker symbol for Alzamend Neuro, Inc. - Common Stock is ALZN on the Nasdaq Stock Market
What is the current price of Alzamend Neuro, Inc. - Common Stock?
The current price of Alzamend Neuro, Inc. - Common Stock is 3.560
When was Alzamend Neuro, Inc. - Common Stock last traded?
The last trade of Alzamend Neuro, Inc. - Common Stock was at 05/22/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.